نظرة عامة

البيانات الصحفية والأخبار

ابق على اطلاع بأحدث الإنجازات والشراكات والمعالم في PGxAI. تعكس بياناتنا الصحفية وتحديثات الأخبار التزامنا المستمر بتحويل الرعاية الصحية من خلال الطب الدقيق القائم على الذكاء الاصطناعي.

البحث حسب العنوان

PGxAI Welcomes Roni Zeiger as Product Strategy Advisor

PGxAI appoints Roni Zeiger—former Meta Head of Health Strategy, former Google Chief Health Strategist, and co‑founder of Smart Patients—as Product Strategy Advisor to strengthen patient‑centered product development and AI strategy in pharmacogenomics.

أبرز النقاط

Led health strategy at Meta (2019–2023) and Google (2006–2012), bringing large‑scale consumer health product expertise

Co‑founded Smart Patients and scaled patient‑to‑patient learning communities to inform community‑driven product design

17 years of frontline clinical practice; currently advises Added Health, Moneta Health, Noora Health, HERA Digital Health, and Streetwyze on product strategy and AI in health

PGxAI Admitted to Creative Destruction Lab (CDL) Seattle — Computational Health 2025–2026

PGxAI has been admitted to the Creative Destruction Lab (CDL) Seattle 2025–2026 program in the Computational Health stream at the University of Washington’s Foster School of Business.

أبرز النقاط

Admitted to CDL Seattle — Computational Health (2025–2026)

The objectives‑based CDL program pairs founders with experienced operators, scientists, and investors to set measurable milestones and accelerate commercialization.

Focus on health‑system co‑development, measurable clinical‑economic KPIs, and scaled PGx deployment

PGxAI Welcomes John Quackenbush as Scientific Advisor

PGxAI appoints John Quackenbush—Harvard biostatistics chair, White House Open Science honoree, and Genospace co-founder—as Scientific Advisor to strengthen multi-omics analytics, reproducibility, and nationwide interoperability.

أبرز النقاط

Leads Harvard Chan Biostatistics; 350+ publications & >103k citations

White House Open Science Champion of Change 2013; NAM member 2022

Advises PGxAI on scalable multi-omics integration, data standards, and clinical decision support

PGxAI and Sequencing.com Announce Strategic Partnership to Advance Affordable Pharmacogenomics

PGxAI and Sequencing.com formed a strategic partnership to introduce PGx reports on Sequencing.com and advance affordable, safer prescribing through pharmacogenomics.

أبرز النقاط

Strategic partnership with Sequencing.com; PGx reports available via the Sequencing.com marketplace.

Focus on ADR reduction and affordability.

Compatibility with popular consumer genetic data formats; new revenue opportunities for genomic labs.

PGxAI Named a Key Player in Straits Research’s Pharmacogenomics (PGX) Market Report

Straits Research included PGxAI among key players in its Pharmacogenomics (PGX) Market report (2025–2033) and profiled the company as an emerging innovator. The report projects market growth from $6.13B (2024) to $11.17B (2033) at a 6.6% CAGR.

أبرز النقاط

PGxAI listed among key players and profiled in Straits Research’s PGX Market report.

Market outlook: $6.13B (2024) to $11.17B (2033), 6.6% CAGR.

Recognition underscores PGxAI’s AI‑enabled, guideline‑driven approach to safer, more effective prescribing.

PGxAI Welcomes David Blumenthal as Scientific Advisor

PGxAI appoints David Blumenthal, former National Coordinator for Health Information Technology, as Scientific Advisor to guide digital-health strategy and integrate precision-medicine innovations with nationwide health IT infrastructure.

أبرز النقاط

Led the implementation of the HITECH Act’s “meaningful use” program, driving nationwide EHR adoption and health‐IT infrastructure modernization

Brings deep expertise in health policy, government advisory roles, and academic thought leadership on digital‐health interoperability

Advises PGxAI on integrating its precision‐medicine platform with national health IT systems and shaping supportive policy frameworks

Benchmarking LLMs for Pharmacogenomic (PGx) Recommendations

- Evaluated 5 leading LLMs on 599 CPIC‑aligned gene–drug–phenotype scenarios to reproduce guideline‑based PGx recommendations. - Introduced a validated semantic evaluation metric (LLM Score) alongside standard lexical metrics. - A domain‑adapted model reached LLM Score 0.92 with significantly faster inference than general‑purpose models.

أبرز النقاط

General‑purpose models frequently produced incomplete or unsafe outputs; domain adaptation improved clinical completeness and safety.

Minimal fine‑tuning + structured prompting markedly increased accuracy and reduced inference time (orders of magnitude).

Establishes a robust evaluation framework for PGx‑specific LLMs and demonstrates the feasibility of safer, AI‑driven personalized medicine.

AI & Multi-Omics in Pharmacogenomics: PGxAI’s New Review

An open-access review in Mayo Clinic Proceedings: Digital Health shows how AI-enabled integration of genomic, transcriptomic, proteomic and metabolomic data is reframing pharmacogenomics. The paper distills recent breakthroughs, real-world evidence and remaining hurdles on the path to routine precision prescribing.

أبرز النقاط

Multi-omics integration captures drug-response biology that single-gene tests miss

GNN, VAE and LLM architectures demonstrably raise prediction accuracy and clinical decision support

Real-world datasets, explainable AI and federated workflows chart feasible routes to bedside adoption

PGxAI Unveils Betelgeuse — New AI Model for Real-Time Clinical Outcome Analysis and Adaptive Recommendations

PGxAI has introduced Betelgeuse, a real-time AI model that analyzes clinical outcomes and adapts treatment recommendations on the fly. Built to complement the previously launched Deneb, Betelgeuse integrates multi-omics and real-world patient data to help healthcare and research teams optimize therapies and reduce adverse event risk by ~30%. The model marks a key advancement in PGxAI’s precision-medicine platform—shifting from prediction to dynamic therapeutic adjustment.

أبرز النقاط

Betelgeuse analyzes clinical outcomes and adjusts treatment recommendations in near real-time

Integrates multi-omics, pharmacogenetic, and historical clinical data for evidence-based decision support

Designed for seamless deployment in pharma, CRO, and healthcare workflows with backing from major tech partners

Upload Your Own Genetic Data: Instant Drug-Sensitivity Insights Now in All Base Models

PGxAI now offers free direct upload of custom genomic files in every base model, delivering instant, compound-specific drug-sensitivity readouts. Paid API endpoints remain available for high-volume, workflow integration.

أبرز النقاط

Supports VCF data from all major platforms

<10 s per-compound sensitivity scoring, expandable to full panels

Scalable, paid REST API and automated reporting for enterprise deployments

Drug-Drug Interaction Module—FDA-Label Powered, Terminal-Ready—Now Live in All Open Models

PGxAI introduces an FDA-label-derived DDI module, offering real-time interaction checks in both open CLI models and enterprise API workflows.

أبرز النقاط

Extracted interaction data from 40,000+ FDA labels, covering 1,300+ unique drugs

<10s risk assessment per query with severity grading and label citations

Free terminal testing for all open models; scalable API available for production deployments

PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Drugs Including Ozempic®

PGxAI has released an AI-driven genetic report that tailors GLP-1 therapies—including semaglutide brands Ozempic® and Wegovy®—to each patient’s genome, flagging high-risk variants and delivering actionable dosing or alternative-drug guidance within minutes via EHR integration.

أبرز النقاط

Identifies risk variants in up to ⅓ of semaglutide patients

Covers 10+ GLP-1, dual-incretin, and CNS-based weight-loss drugs

Real-time decision support through InterSystems HealthShare

PGxAI Debuts Deneb, an AI Model Revolutionizing Drug Development for Biopharma

PGxAI has launched Deneb, an AI pharmacogenetics model for biopharma and CROs that fuses molecular, physicochemical, and genomic data to deliver real-time PGx guidance, cutting trial costs and speeding drugs to market.

أبرز النقاط

Real-time PGx insights for cohort, dose, safety

Automates multi-omics + structure data; shortens trials

Powered by NVIDIA, Microsoft, InterSystems stack

Automated Phenoconversion Arrives: Real-Time, Context-Aware Drug-Response Scoring in Every Base Model

PGxAI has embedded automated phenoconversion in all base models, instantly recalibrating genotype-based predictions to reflect co-medications and clinical modifiers; the feature is live in the web portal and available via enterprise REST API.

أبرز النقاط

Context-aware phenotype adjustment for CYP450 and 20+ additional enzymes

<10 s recalculation per drug, supporting batch analysis through paid API

Seamless upgrade—no extra configuration for existing base-model users

PGxAI Debuts Vega, an AI Model Set to Disrupt Precision Medicine

PGxAI has unveiled Vega, an AI-powered pharmacogenetics model that instantly converts a patient’s genomic data into drug-specific treatment recommendations, covering 1,200 drugs and 350 genes—vastly surpassing traditional panels.

أبرز النقاط

1,200 drugs / 350 genes analyzed in minutes

Cuts adverse-reaction risk via automated guideline interpretation

Built with GenAI; integrates into EHRs through InterSystems HealthShare

Revolutionizing Precision Medicine: PGxAI Raises $1.5 Million in Funding for AI-Powered Pharmacogenetics Platform

PGxAI has raised $1.5 million to scale its AI-powered pharmacogenetics platform, funding upgrades to its VectorSearch and GenAI tools and deepening its partnership with InterSystems to deliver ultra-precise, genome-guided prescribing.

أبرز النقاط

$1.5M round accelerates tech development

Boosts VectorSearch & GenAI for dose, drug-selection, DDI insights

Leverages InterSystems’ vast patient data to sharpen precision medicine

The Ventures Award: The World's Premier Stage for Startup Excellence

PGxAI captured the top prize at The Ventures Award—Silicon Valley’s roaming startup showcase—outshining hundreds of global contenders with its AI-powered pharmacogenomics platform. The tour now heads to Chicago on 7 Feb 2025 before expanding to other tech hubs worldwide.

أبرز النقاط

PGxAI wins flagship Ventures Award

30-city, 19-country pitch circuit

Next event: Chicago, 7 Feb 2025

PGxAI Launches Sirius, an AI‑Powered Pharmacogenetics Model

PGxAI has launched Sirius, an AI-driven pharmacogenetics model that tailors drug choice, dosage, and interaction management to each patient’s genome, enabling ultra-precision prescribing for hospitals, labs, and CROs.

أبرز النقاط

Covers 730 drugs and 40 key pharmacogenes—more than twice the scope of typical solutions—aiming to avert up to 30% of adverse drug reactions.

Leverages partnerships with Nvidia, Microsoft, Google, Meta, AWS, and InterSystems, integrating seamlessly into EHR workflows via HealthShare.

Ambitious roadmap: expand to 1 700 drugs in 2025, add GenAI and federated-learning upgrades by 2026, and harness >1 billion real-world outcomes by 2030.

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration

BioStrand (ImmunoPrecise) and PGxAI are partnering to build an AI-driven pharmacogenomics model on BioStrand’s LENSai platform to deliver personalized drug-response predictions and speed up LENSai API adoption.

أبرز النقاط

Integrates LENSai’s multi-omics AI with PGxAI’s real-world genomic data to forecast efficacy, dose, and safety.

Aims to cut the >30% rate of drug-related adverse events and improve precision prescribing.

Targets the $400B prescription market, unlocking new revenue as the LENSai API scales.

ابق على اتصال

نتطلع إلى المستقبل، مهمتنا لا تزال ثابتة

ابق على اطلاع بأحدث الإنجازات والشراكات والمعالم في PGxAI. تعكس بياناتنا الصحفية وتحديثات الأخبار التزامنا المستمر بتحويل الرعاية الصحية من خلال الطب الدقيق القائم على الذكاء الاصطناعي.

تحديثات البريد الإلكتروني

اشترك في نشرتنا الإخبارية للحصول على رؤى شهرية وإطلاق المنتجات والأحداث القادمة.

لينكد إن

تابع PGxAI للحصول على تحديثات في الوقت الفعلي حول اتجاهات الصناعة وإعلانات الشركة.

استفسارات وسائل الإعلام

للعلاقات الصحفية والإعلامية، أرسل بريدًا إلكترونيًا إلى admin@pgx.ai أو اتصل بالرقم +1 (415) 246-5322.

تواصل معنا

هل أنت مستعد لتشكيل مستقبل الطب الدقيق؟

تستمر PGxAI في التطور مع كل تطوير، مما يعزز مهمتنا لتقديم رعاية شخصية تفيد المرضى ومقدمي الخدمات وجميع أصحاب المصلحة في النظام البيئي للرعاية الصحية.

راسلنا عبر البريد الإلكتروني: admin@pgx.ai

اتصل بنا: +1 (415) 246-5322

جدولة عرض توضيحي